Post-transplant acute limbic encephalitis: Difference between revisions

From IDWiki
()
No edit summary
Line 2: Line 2:
   
 
== Background ==
 
== Background ==
* Caused by [[HHV-6B]]
+
* Caused by [[HHV-6B]][[CiteRef::ongrádi2016ro]]
   
 
== Clinical Presentation ==
 
== Clinical Presentation ==
Line 14: Line 14:
 
* Treat any possible concomitant risk factors such as hyponytremia
 
* Treat any possible concomitant risk factors such as hyponytremia
 
* Antivirals: [[Is treated by::acyclovir]], [[Is treated by::ganciclovir]], or [[Is treated by::foscarnet]] for 10 days to 4 weeks
 
* Antivirals: [[Is treated by::acyclovir]], [[Is treated by::ganciclovir]], or [[Is treated by::foscarnet]] for 10 days to 4 weeks
  +
  +
== Further Reading ==
  +
* Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. ''Neurology''. 2007;69(2):156-165. DOI: [https://doi.org/10.1212/01.wnl.0000265591.10200.d7 10.1212/01.wnl.0000265591.10200.d7]
   
 
[[Category:Immunocompromised hosts]]
 
[[Category:Immunocompromised hosts]]

Revision as of 20:06, 10 February 2020

  • Limbic encephalitis syndrome following hematopoietic stem cell transplantation

Background

Clinical Presentation

  • Onset 2 weeks to 2 months after transplant
  • Presents with confusion, amnesia, hallucinations
  • Can cause seizures
  • Hyponatremia is common

Management

  • Treat seizures with antiepileptic medications
  • Treat any possible concomitant risk factors such as hyponytremia
  • Antivirals: acyclovir, ganciclovir, or foscarnet for 10 days to 4 weeks

Further Reading

References

  1. ^  Joseph Ongrádi, Dharam V. Ablashi, Tetsushi Yoshikawa, Balázs Stercz, Masao Ogata. Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals. Journal of NeuroVirology. 2016;23(1):1-19. doi:10.1007/s13365-016-0473-0.